Icecure Medical is trading 14.2% up at $3.17 as it rebounds from a recent pullback and tracks a broader risk-on rally in U.S. equities.
- The upward move is primarily driven by improving market sentiment and strong macro data, leading investors to re-enter riskier names following a period of profit-taking.
- There are no fresh company-specific catalysts, earnings reports, or FDA decisions recorded for August 4, 2026.